
Tymora Analytical Operations LLC Profile last edited on: 12/5/2019
CAGE: 66R81
UEI: ZFFZKDYTF5Q9
Business Identifier: Diagnostic exosome biomarker discovery services in liquid biopsy field Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1201 Cumberland Avenue
West Lafayette, IN 47906
West Lafayette, IN 47906
(765) 490-6834 |
customersupport@tymora-analytical.com |
www.tymora-analytical.com |
Location: Single
Congr. District: 04
County: Tippecanoe
Congr. District: 04
County: Tippecanoe
Public Profile
Tymora Analytical Operations LLC is structured to provide diagnostic development and exosome proteomics contract services and products for improved cancer research. Wiith a primary objective being to enable the shift from tissue to liquid biopsy, the firms new technologies allow detection of active exosome protein and phosphoprotein cancer markers directly from plasma, urine or saliva. As a platform to discover, validate and routinely detect diagnostic markers, the firm's approach offers important potential to find signaling proteins in biofluids that were not previously accessible. Designed to provide novel, highly-effective and cost-efficient approaches to carrying out proteomic and phosphorylation analyses, Tymora is undertaking further development new applications of the technologies. The firm is receptive to collaborations with partners interested in Tymora's technology for design and validation of early disease detection tests, cancer monitoring post-treatment, or for companion diagnostic assays for pipeline therapies.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 2 | NIH | $1,030,397 | |
Project Title: Development of Non-Invasive Research and Diagnostics Platform for Alzheimer's Disease Based on Plasma Exosomes | ||||
2022 | 1 | NIH | $290,000 | |
Project Title: Development of lavage EV protein biomarkers for minimally-invasive detection of endometrial cancer | ||||
2021 | 2 | NIH | $1,524,999 | |
Project Title: Development of Non-Invasive Biomarker Discovery and Diagnostics Approach for Bladder Cancer Based on Urine Proteome and Phosphoproteome | ||||
2021 | 1 | NIH | $310,000 | |
Project Title: Development of companion diagnostics for dasatinib-based personalized therapy for T-ALL | ||||
2020 | 1 | NIH | $299,975 | |
Project Title: Developing High Throughput Measurement Of Thiopurine In Dna By Mass Spectrometry |
Key People / Management
Anton Iliuk -- President; Chief Technology Officer
David Giddings -- Chief Business Officer
Peter Kissinger -- Business and Commercialization Mentor
W Andy Tao -- Chief Scientific Officer
Vicky Tseng
David Giddings -- Chief Business Officer
Peter Kissinger -- Business and Commercialization Mentor
W Andy Tao -- Chief Scientific Officer
Vicky Tseng
Company News
There are no news available.